Linagliptin is used for the management of type 2 diabetes mellitus.
Linagliptin inhibits glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GIP).
The drug augments incretin levels and facilitates insulin secretion.
GLP-1 and GIP promotes normal insulin secretion from beta cells of pancreas and reduces liver glucose output.
Linagliptin is contraindicated in patients with history of pancreatitis and hyperlipidemia or dyslipidemia.
Linagliptin may interact with
St. John’s wort,
anti-epileptic drugs and cyclosporine.
Linagliptin can cause serious hypoglycemia, if taken concomitantly with MAOIs, sulfa drugs, NSAIDs, probenecid, salicylates, beta-blockers and other glipizides.
Do not consume alcohol while taking Linagliptin. It can cause serious hypoglycemia.
Therapeutic Classification : Antidiabetic
Pharmacological Classification :dipeptidyl peptidase-4 (DDP-4) inhibitors
After oral administration, the drug is moderately absorbed in the GIT.
The protein binding capability, Cmax and Vss, depends on the concentration and route of administration.
The drug is mostly excreted in urine as unchanged drug.
Copyright ©Nims Drugs2015. All rights reserved.
Powered by : web creation Nepal